GDNF and amyotrophic lateral sclerosis: Indeed, two ongoing Phase I/IIa trials (NCT03482050, with GDNF overexpression NCT02943850) currently examine the therapeutic potential of grafted human stem cell derived astrocytes for the treatment of ALS.